miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 24, 2026

CRWV vs. MSFT: Which AI Infrastructure Stock is the Better Buy?

View original at finance.yahoo.com
CRWV vs. MSFT: Which AI Infrastructure Stock is the Better Buy? Behind every generative AI model and autonomous system is massive compute infrastructure, especially data centers full of GPUs that train and serve models…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • In terms of valuation, CRWV seems to be a better pick at the moment

    80% confidence
  • CRWV looks better positioned for near-term outperformance because we are in the AI capacity-deployment phase

    80% confidence
  • Active power is expected to exceed 850 MW by year-end

    80% confidence
  • The Core Scientific acquisition decision does not affect its growth outlook

    80% confidence
  • Spending on AI data centers and accelerated computing is surging, creating a multitrillion-dollar opportunity

    80% confidence
  • MSFT remains the stronger long-term buy, with AI monetization through Azure and Copilot, massive RPO visibility and diversified cash flows

    80% confidence
  • Management remains upbeat about ongoing growth across commercial and enterprise segments, driven by global capacity buildout and multiple revenue pillars

    80% confidence
  • Management remains confident in its ability to meet long-term demand, scale capacity and strengthen its position in AI cloud as new offerings, partnerships and federal deals ramp

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com